Visualization of Operating Room Air

HUAIRS system was utilized during two orthopedic procedures. After each surgical case the air inlet filtration cartridge was analyzed for deposited debris via scanning electron microscopy. Significant particle contamination was evident after each orthopedic procedure. Various types and morphologies of particles suggest that they originated from multiple sources. Suspected cell-derived fragments were evident.

Reduction of Viable Particles in Active Operating Room

Deployment of HEPA/UV-C Air Recirculation System (HUAIRS) in active urology operating room (OR) resulted in ˃ 95% reduction in 1 µm, 3 µm and 10 µm viable particulates as well as 84% decrease in air content of 5 µm particles. The decline in airborne particle contamination strongly correlated with bacterial quantification results in support of the efficacy of HUAIRS in improving OR air quality.

Measuring Particulates during Surgery

Airborne particulates generated during a range of orthopedic, spinal and plastic surgery procedures was measured with and without the HEPA Ultraviolet Recirculation System (HUAIRS). This evaluation found procedure and environment influences airborne particles and using the HUAIRS, total and viable particulates were reduced.


President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.


Vice President of Sales

Nathan brings a high level of commitment to servicing and building client relations. He was one of the first employees to start for Aerobiotix. Nathan has previously held leadership roles in the medical device industry. He received his BS from Antioch McGregor University Midwest.


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.